An advisory panel of academicians, private practice physicians, podiatrists, nurse clinicians, research nurses, industrial scientists, and an epidemiologist was chosen to develop guidelines for the treatment of venous ulcers of the lower extremity.
There were major differences between our approach to evidence citations and past approaches to evidence-based guidelines. Most past approaches relied only on publications regarding clinical human studies. Laboratory or animal studies were not cited. We have used wellcontrolled animal studies that present proof of principle, especially when a clinical series corroborated the laboratory results. It was also clear that principles that have been validated for other chronic wound types often are applicable to venous ulcers. Therefore, evidence was sometimes cited that was not specific for venous ulcers. Because of these variations, a different system was used to grade the evidence weight supporting a given guideline. The level strength of evidence supporting a guideline is listed as Level I, Level II, or Level III. The guideline levels are:
Level I: Meta-analysis of multiple RCTs or at least two RCTs support the intervention of the guideline. Another route would be multiple laboratory or animal experiments with at least two clinical series supporting the laboratory results.
Level II: Less than Level I, but at least one RCT and at least two significant clinical series or expert opinion papers with literature reviews supporting the intervention. Experimental evidence that is quite convincing, but not yet supported by adequate human experience is included. Level III: Suggestive data of proof of principle, but lacking sufficient data such as meta-analysis, RCT, or multiple clinical series. NB: The suggestion in the guideline can be positive or negative at the proposed level (e.g., meta-analysis and two RCTs stating intervention is not of use in treating venous ulcers).
RESULTS
Guidelines have been formulated in eight categories for the treatment of venous ulcers of the lower extremities. 
GUIDELINES FOR THE DIAGNOSIS OF LOWER EXTREMITY VENOUS ULCERS
Preamble: Ulcers of the lower extremity may be caused by a variety of conditions. Elevation of ambulatory venous pressure (venous hypertension) is the most common. However, as treatment of the ulcer may vary depending on ulcer etiology, it is paramount that a correct diagnosis is made before treatment.
Guideline #1.1: Gross arterial disease should be ruled out by establishing that pedal pulses are present on physical examination and/or that the ankle : brachial index (ABI) is > 0.8. (Any ABI less than 1.0 suggests a degree of vascular disease and compression therapy is usually considered to be contraindicated with an ABI < 0.7.) In elderly patients, patients with diabetes mellitus, or patients with an ABI > 1.2, a toe : brachial index of > 0.6 or a trans-cutaneous oxygen partial pressure of > 30 mmHg in the region of the ulcer may help to suggest an adequate arterial flow (Level I).
Principle: Venous ulcers can exist in the presence of mixed arterial/venous pathology. However, treatment of only the elevated venous pressure will not succeed when significant arterial disease is present. Guideline #1.2: Many definitions have been used to diagnose venous leg ulcers including clinical history and examination, invasive, and noninvasive testing. It is important to understand how the diagnosis was made and to understand the limitations of the method. Color duplex ultrasound scanning performed with proximal compression or a Valsalva maneuver is useful in providing anatomic and physiologic data helping to confirm a venous etiology for the leg ulcer (Level I).
Evidence
Principle: Although clinical history and physical examination can be very suggestive of a venous etiology of the lower extremity ulcer after insufficient arterial inflow has been eliminated, a definitive diagnosis of the venous disease is desirable. This is not always possible. When using various tests to document venous disease, it is paramount that the information needed by the clinician be clearly communicated to the test performer. Guideline #1.5: Apparent venous ulcers, as well as all wounds, that are excessively painful and that progressively increase in size after debridement and/or despite treatment should be considered for other diagnoses such as pyoderma gangrenosum, IgA monoclonal gammopathies, Wegener's granulomatosis, cutaneous chronic granulomatous disease, and mycobacterial or fungal etiologies. This suspicion should be especially high if the ulcer is darker in color, has blue/purple borders, or if the patient has a systemic disease such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, collagen vascular diseases, leukemia, or immunosuppression (Level II).
Principle: Leg ulcers that worsen in size and symptoms despite treatment, or do not show any improvement over 4 weeks of treatment, should raise suspicion that the ulcer etiology is not venous in origin or that the therapy needs to be re-evaluated. At this point, specific cultures for mycobacteria and/or fungi are useful, as biopsies for histology. 
GUIDELINES FOR LOWER EXTREMITY COMPRESSION FOR TREATMENT OF VENOUS ULCERS
Preamble: Venous ulceration results from an elevated ambulatory venous pressure (venous hypertension). This frequently causes edema of the limb. External compression has been the mainstay to combat these problems.
Guideline #2.1: The use of a Class 3 (most supportive) high-compression system (three layer, four layer, short stretch, paste-containing bandages, e.g., Unna's boot, Duke boot) is indicated in the treatment of venous ulcers. Although these modalities are similar in effectiveness, they can differ significantly in comfort and cost. The degree of compression must be modified when mixed venous/arterial disease is confirmed during the diagnostic work-up (Level I).
Principle: Venous ulcer healing is increased when adequate compression is applied to the lower extremity. Guideline #2.2: Intermittent pneumatic pressure (IPC) can be used with or without compression dressings and can provide another option in patients who cannot or will not use an adequate compression dressing system (Level I).
Principle: Intermittent pressure stimulates venous return and can be utilized when constant compression is not tolerated. Guideline #3.2: If infection is suspected in a debrided ulcer, or if epithelialization from the margin is not progressing within 2 weeks of debridement and initiation of compression therapy, determine the type and level of infection in the debrided ulcer by tissue biopsy or by a validated quantitative swab technique (Level II).
Evidence
Principle: High levels of bacteria !1Â10 6 CFU/g of tissue or any tissue level of beta hemolytic streptococci impede the various wound-healing processes and have been demonstrated to impede spontaneous healing and surgical closure of venous ulcers. Cultures should be performed to isolate both aerobic and anaerobic bacteria.
Evidence: Guideline #3.3: For ulcers with !1Â10 6 CFU/g of tissue or any tissue level of beta hemolytic streptococci following adequate debridement, decrease the bacterial level with topical antimicrobial therapy. Once in bacterial balance, discontinue the use of the topical antimicrobial agent to minimize any possible cytotoxic effects due to the antimicrobial agent or emergence of bacterial resistance to the agent (Level I).
Principle: Systemically administered antibiotics do not effectively decrease bacterial levels in granulating wounds; however, topically applied antimicrobials can be effective. Guideline #3.5: Minimize the tissue level of bacteria, preferably to 10 5 CFU/g of tissue, with no beta hemolytic streptococci in the venous ulcer before attempting surgical closure by skin graft, skin equivalent, pedicled, or free flap (Level II).
Principle: ''A wound containing contaminated foci with greater than 10 5 organisms per gram of tissue cannot be readily closed, as the incidence of wound infection that follows is 50-100%'' Tobin (1984) . Preamble: Wound bed preparation is defined as the management of the wound to accelerate endogenous healing or to facilitate the effectiveness of other therapeutic measures. The aim of wound bed preparation is to convert the molecular and cellular environment of a chronic wound to that of an acute healing wound. The principles of wound bed preparation have been enumerated:
Principle: (A) A general medical history and physical examination, including a medication record, will help in identifying and correcting systemic causes of impaired healing. The presence of a major illness or systemic disease and drug therapies such as immunosuppressive drugs and systemic steroids will interfere with wound healing by alterations in immune functioning, metabolism, inflammation, nutrition, and tissue perfusion. Autoimmune diseases such as rheumatoid arthritis, uncontrolled vasculitis, or pyoderma gangrenosum can all delay healing and may require systemic steroids or immunosuppressive agents before local wound healing can occur. Patients undergoing major surgery have a diminished wound-healing capacity as do chronic smokers. This information in addition to a detailed history of the wound itself is of benefit. Principle: (C) Wounds will heal in an environment that is adequately oxygenated. Oxygen delivery to a wound will be impaired if tissue perfusion is inadequate. Dehydration and factors that increase sympathetic tone such as cold, stress, or pain will all decrease tissue perfusion. Cigarette smoking decreases tissue oxygen by peripheral vasoconstriction. For optimal tissue perfusion, these factors must be eliminated or minimized. Guideline #4.2: Initial debridement is required to remove the obvious necrotic tissue, excessive bacterial burden, and cellular burden of dead and senescent cells. Maintenance debridement is needed to maintain the appearance and readiness of the wound bed for healing. The health care provider can choose from a number of debridement methods including sharp, enzymatic, mechanical, biological, or autolytic. More than one debridement method may be appropriate (Level I).
Principle: Necrotic tissue, excessive bacterial burden, senescent cells, and cellular debris can all inhibit wound healing. Sharp debridement is often the most advantageous. However, the method of debridement chosen may depend on the status of the wound, the capability of the health provider, the overall condition of the patient, and professional licensing restrictions. Excessive debridement can result in a reinstitution of the inflammatory process with a consequent influx of inflammatory cytokines. Principle: Irrigating and cleansing the wound removes loose impediments to wound healing. Sterile saline or water is usually recommended. Tap water should only be used if the water source is reliably clean. Experimental data suggest that a nontoxic surfactant may be useful as may fluid delivered by increased intermittent pressure. Guideline #4.4: There should be an ongoing and consistent documentation of wound history, recurrence, and characteristics (location, size, base, exudates, condition of the surrounding skin, staging, and pain) to evaluate wound bed preparation. The rate of wound healing should be evaluated to determine whether treatment is optimal (Level I).
Principle: Ongoing evaluations of wound bed preparation are necessary because if the ulcer is not healing at the expected rate, interventions for wound bed preparation need to be reassessed. The longer the duration of the ulcer, the more difficult it is to heal. If an ulcer is recurrent, patient education or issues of prevention and long-term maintenance need to be reassessed. 

GUIDELINES FOR DRESSINGS IN THE TREATMENT OF VENOUS ULCERS
Preamble: There is a plethora of choices for topical treatment of venous ulcers. Many dressings now combine wound bed preparation, i.e., debridement and/or antimicrobial activity, with moisture control. Guidelines are necessary to help the clinician make decisions regarding the value and best use of these advanced wound care products. Most dressings will be used in combination with compression systems (see Compression Guidelines).
Guideline # 5.1: Use a dressing that will maintain a moist wound-healing environment (Level I).
Principle: A moist wound environment physiologically favors cell migration and matrix formation while accelerating healing of wounds by promoting autolytic debridement. Moist wound healing also reduces pain. Dry dressings, except over intact skin, are considered injurious and can cause desiccation of the wound. Guideline #5.5: Select a dressing that is cost effective and appropriate to the setting and the provider (Level I).
Principle: Because of their low unit cost, moist saline gauze dressings are often viewed as the least expensive and, therefore, most cost-effective dressing. However, as pointed out in Guideline #5.2, it is very difficult to keep a gauze dressing continuously moist. When determining cost effectiveness, it is important to take into consideration health care provider time, ease of use, and healing rate, as well as the unit cost of the dressing. Guideline #5.6: Selectively use adjuvant agents (topical, device, and/or systemic) after evaluating individual patient/ulcer characteristics and when there is a lack of healing progress in response to more traditional therapies. (Detailed discussions of these alternatives are in Adjuvant Agents [Topical, Device, Systemic] Guidelines; Level I.)
Evidence
Principle: Emerging therapies through recombinant technologies and cell-based devices may offer benefit and increase healing in selected patients or difficult wounds. These therapies are quite diverse and are discussed in detail in the Adjuvant Agents Guidelines.
Evidence: Evidence references are detailed in the Adjuvant Agents (Topical, Device, Systemic) Guidelines.
GUIDELINES FOR SURGERY IN THE TREATMENT OF VENOUS ULCERS
Preamble: The mainstays of moist wound dressings and a compression system are not successful in healing all venous ulcers. Also, they do not fully address the etiology of increased ambulatory venous pressure. Over the years, multiple surgical procedures have been attempted to treat venous ulcers with varying degrees of success. True randomized clinical trials comparing operative techniques are rare in the literature, but data are available supporting surgery in selected patients. These data include a crossover study (DePalma RG, Kowallek DL. Venous ulceration: a cross-over study from nonoperative to operative treatment. J Vasc Surg 1996; 24: 788-92).
Guideline #6.1: Skin grafting of a venous ulcer, without attention to the underlying venous disease, is not a long-term solution and is prone to recurrent leg ulceration (Level I).
Principle: Closing the venous ulcer with an autologous skin graft (pinch graft, split-thickness graft, meshed graft, full-thickness graft) may provide a short-term goal of wound closure but does not address the increased ambulatory venous pressure (venous hypertension) that is the underlying cause of the ulcer. Preamble: Many agents have been suggested for use as adjuvants to moist wound-healing dressings and compression therapy in the treatment of venous ulcers. These adjuvant agents can be divided into topical agents to be applied to the ulcer, devices aimed at accelerating ulcer healing, and systemic drugs to treat the patient. Several of these agents have enough evidence to allow guidelines regarding their use to be developed.
TOPICAL AGENTS
Guideline #7a.1: Cytokine growth factors have yet to be shown to demonstrate sufficient statistically significant results of effectiveness to recommend any of them for treatment of venous ulcers, although isolated reports suggest their potential usefulness (Level I).
Principle: Cytokine growth factors are messengers/mediators of the wound-healing scheme. They have been shown to be deficient or trapped in chronic wounds, so theoretically they could be useful for treatment of venous ulcers, and several authors have reported positive results in small series.
Evidence:
